Recombinant Human Long-chain-fatty-acid–CoA ligase 4 (ACSL4), Truncated

Uniprot Id

O60488

Target Species

Human

Target Name

ACSL4

Target Full Name

Long-chain-fatty-acid--CoA ligase 4

Target Function

Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially activates arachidonate and eicosapentaenoate as substrates. Preferentially activates 8,9-EET > 14,15-EET > 5,6-EET > 11,12-EET. Modulates glucose-stimulated insulin secretion by regulating the levels of unesterified EETs. Modulates prostaglandin E2 secretion.

Target Involvement

Mental retardation, X-linked 63 (MRX63); Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR)

Target Subcellular Location

Mitochondrion outer membrane; Single-pass type III membrane protein. Peroxisome membrane; Single-pass type III membrane protein. Microsome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein. Cell membrane.

Target Protein Families

ATP-dependent AMP-binding enzyme family

Target Synonyms

ACSL4; ACS4; FACL4; LACS4; Long-chain-fatty-acid--CoA ligase 4; Arachidonate--CoA ligase; Long-chain acyl-CoA synthetase 4; LACS 4

Target Background

The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme preferentially utilizes arachidonate as substrate. The absence of this enzyme may contribute to the cognitive disability or Alport syndrome. Alternative splicing of this gene generates multiple transcript variants.